Menu

Dr. W. Thomas Purcell currently serves as Associate Director for Clinical Services of the University of Colorado Cancer Center and Executive Medical Director of Oncology Services at University of Colorado Hospital. Prior to joining the University of Colorado in 2012, Dr. Purcell received training for Internal Medicine and Medical Oncology at Emory University School of Medicine and Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center.

Also prior to his position at University of Colorado, Dr. Purcell spent seven years as the Director of the Billings Clinic Cancer Center, where he was also part of the executive leadership at the clinic as Division Chief for Service Lines Growth, as well as a Foundation Board Member. Through this experience and more, Dr. Purcell has been able to build an extensive knowledge in various cancers and diseases, contributing to many different publications.

Main Speciality: Medical Oncology

Other Interests & Specialties: Internal medicine, anal cancer, biliary cancer, cancer medication, chemotherapy, gastroenterologic cancer (colon, stomach, esophageal, liver), lung cancer and pancreatic cancer.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Certification in Cancer Oncology, American Board of Internal Medicine Certification in Medical Oncology, member of American Society of Clinical Oncology, recipient of ASCO’s Statesman Award

Education & Experience:

  • Medical Degree from Emory University School of Medicine
  • Internship at University of Texas Southwestern Medical School Program
  • Residency in Internal Medicine at University of Texas Southwestern Medical School Program
  • Fellowship for Medical Oncology at Johns Hopkins University School of Medicine Program

Publications:
Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab GovitecanClinical Cancer Research. July 2017;23(19): doi: 10.1158/1078-0432.CCR-17-0933

The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinibJournal of Thoracic Oncology. July 2018;13(11):1717-1726. doi: 10.1016/j.jtho.2018.07.001

Brief Report: Baseline and on treatment characteristics of serum tumor markers in stage IV oncogene-addicted adenocarcinoma of the lungJournal of Thoracic Oncology. January 2018;13(1):134-138. doi: 10.1016/j.jtho.2017.08.005

Photo of Dr. W. Thomas Purcell

Get Help Contacting Dr. W. Thomas Purcell


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe